Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07269470
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Key Dates

First listed
Dec 8, 2025
Start date
Jul 13, 2026
Status verified
Aug 2026
Primary completion
Nov 1, 2029
Completion
Nov 1, 2029

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Phase 2 Treatment with Dasatinib (PO) + Ropeginterferon (SC)
    Participants will receive treatment on an outpatient basis.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Fadi Haddad, MD
[email protected]
713-792-0970
Fadi Haddad, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials
By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies